ART123

05/13/2020 - "The main effect of the administration of ART-123 may be beneficial for survival outcome in patients with sepsis. "
05/13/2020 - "The purpose of this study was to evaluate the effect modification between ART-123 and PMX-HP treatment on the survival outcome of sepsis using post hoc analysis of the dataset of the Japan Septic Disseminated Intravascular Coagulation registry. "
05/13/2020 - "Although recently published randomised controlled trials did not confirm significant positive effect of ART-123 or polymyxin B‑immobilised haemoperfusion (PMX-HP) on survival outcome, previous studies using a dataset of 3195 patients with sepsis registered at 42 intensive care units throughout Japan revealed significantly reduced mortality following these treatments. "
05/13/2020 - "Beneficial effect modification on survival outcome of sepsis between ART-123 and polymyxin B‑immobilised haemoperfusion: a nationwide Japanese registry study."
09/01/2013 - "ART-123 is a safe intervention in critically ill patients with sepsis and suspected disseminated intravascular coagulation. "

05/13/2020 - "The purpose of this study was to evaluate the effect modification between ART-123 and PMX-HP treatment on the survival outcome of sepsis using post hoc analysis of the dataset of the Japan Septic Disseminated Intravascular Coagulation registry. "
09/01/2013 - "ART-123 is a safe intervention in critically ill patients with sepsis and suspected disseminated intravascular coagulation. "
09/01/2013 - "A randomized, double-blind, placebo-controlled, Phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation."

01/01/2007 - "Patients in the ART-123 group also showed more marked improvement in clinical course of bleeding symptoms (P = 0.0271). "
01/01/2007 - "The incidence of bleeding-related adverse events up to 7 days after the start of infusion was lower in the ART-123 group than in the heparin group (43.1% vs. 56.5%, P = 0.0487). "
01/01/2019 - "In conclusion, this study suggests that ART-123 is unlikely to provoke bleeding in patients undergoing liver transplantation because proposed clinical dosages have a virtually absent anticoagulant effect in these patients. "
01/01/2007 - "When compared with heparin therapy, ART-123 therapy more significantly improves DIC and alleviates bleeding symptoms in DIC patients."

05/01/2005 - "This study was performed to identify an effective and safe dose of ART-123 for prevention of venous thromboembolism after elective, unilateral total hip replacement. "

01/01/2007 - "Patients in the ART-123 group also showed more marked improvement in clinical course of bleeding symptoms (P = 0.0271). "